GeneDx Faces Securities Class Action Over Alleged Misleading Statements

The legal action centers on disclosures made during the company’s first-quarter 2026 financial report released on May 4, 2026. According to the complaint, GeneDx revealed a significant decline in adjusted gross margins, lowered its earnings projections, and disclosed a $31.3 million impairment charge tied to Fabric Genomics. Plaintiffs argue these revelations exposed previous public statements as materially misleading, causing financial damages to shareholders when the true state of the company's fiscal health became apparent.

Brian Schall of the Los Angeles-based Schall Law Firm is leading the outreach for potential plaintiffs. Shareholders have until August 3, 2026, to contact the firm regarding the litigation. As the class has not yet been certified, investors currently remain absent class members and are not represented by counsel unless they actively choose to participate in the proceedings.